Genetic variation in PFKFB3 impairs antifungal immunometabolic responses and predisposes to Invasive Pulmonary Aspergillosis by Gonçalves, Samuel M. et al.
Genetic Variation in PFKFB3 Impairs Antifungal
Immunometabolic Responses and Predisposes to Invasive
Pulmonary Aspergillosis
Samuel M. Gonçalves,a,b Daniela Antunes,a,b Luis Leite,c Toine Mercier,d,e Rob ter Horst,f,g Joana Vieira,h Eduardo Espada,h
Carlos Pinho Vaz,c Rosa Branca,c Fernando Campilho,c Fátima Freitas,i Dário Ligeiro,j António Marques,k Frank L. van de Veerdonk,f,g
Leo A. B. Joosten,f,g Katrien Lagrou,e,l,m Johan Maertens,d,e Mihai G. Netea,f,g,n João F. Lacerda,h,o António Campos, Jr.,c
Cristina Cunha,a,b Agostinho Carvalhoa,b
aLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
bICVS/3B’s - PT Government Associate Laboratory, Guimarães/Braga, Portugal
cServiço de Transplantação de Medula Óssea (STMO), Instituto Português de Oncologia do Porto, Porto, Portugal
dDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium
eDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
fDepartment of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
gRadboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
hServiço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Lisbon, Portugal
iInstituto Português do Sangue e Transplantação (IP), Porto, Portugal
jInstituto Português do Sangue e Transplantação (IP), Lisbon, Portugal
kServiço de Imuno-Hemoterapia, Hospital de Braga, Braga, Portugal
lClinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
mNational Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium
nDepartment for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany
oInstituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
ABSTRACT Activation of immune cells in response to fungal infection involves the
reprogramming of their cellular metabolism to support antimicrobial effector func-
tions. Although metabolic pathways such as glycolysis are known to represent criti-
cal regulatory nodes in antifungal immunity, it remains undetermined whether these
are differentially regulated at the interindividual level. In this study, we identify a key
role for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the
immunometabolic responses to Aspergillus fumigatus. A genetic association study
performed in 439 recipients of allogeneic hematopoietic stem cell transplantation
(HSCT) and corresponding donors revealed that the donor, but not recipient,
rs646564 variant in the PFKFB3 gene increased the risk of invasive pulmonary asper-
gillosis (IPA) after transplantation. The risk genotype impaired the expression of
PFKFB3 by human macrophages in response to fungal infection, which was corre-
lated with a defective activation of glycolysis and the ensuing antifungal effector
functions. In patients with IPA, the risk genotype was associated with lower concen-
trations of cytokines in the bronchoalveolar lavage fluid samples. Collectively, these
findings demonstrate the important contribution of genetic variation in PFKFB3 to
the risk of IPA in patients undergoing HSCT and support its inclusion in prognostic
tools to predict the risk of fungal infection in this clinical setting.
IMPORTANCE The fungal pathogen Aspergillus fumigatus can cause severe and life-
threatening forms of infection in immunocompromised patients. Activation of glycol-
ysis is essential for innate immune cells to mount effective antifungal responses. In
this study, we report the contribution of genetic variation in the key glycolytic acti-
vator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) to the risk of
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invasive pulmonary aspergillosis (IPA) after allogeneic hematopoietic stem cell trans-
plantation. The PFKFB3 genotype associated with increased risk of infection was cor-
related with an impairment of the antifungal effector functions of macrophages in
vitro and in patients with IPA. This work highlights the clinical relevance of genetic
variation in PFKFB3 to the risk of IPA and supports its integration in risk stratification
and preemptive measures for patients at high risk of IPA.
KEYWORDS immunometabolism, PFKFB3, Aspergillus, invasive pulmonary aspergillosis,
stem cell transplantation, single nucleotide polymorphism, macrophage, antifungal
immunity
Recent advances in medicine and the introduction of broad-spectrum antibioticshave prompted an increasing incidence of invasive fungal infections, particularly
among hematological patients with chemotherapy or patients undergoing solid organ
or allogeneic hematopoietic stem cell transplantation (HSCT) (1). Invasive pulmonary
aspergillosis (IPA) is a major cause of mortality in these clinical settings, with rates esti-
mated between 20 and 30% (2, 3) but that can reach 80% when infection involves az-
ole-resistant strains (4). The clinical relevance of these infections is further emphasized
by limitations in available tests for the diagnosis of IPA. The development of more
effective medical interventions is therefore an urgent need that demands an improved
understanding of the pathogenesis of IPA.
The reprogramming of immune cell metabolism is acknowledged as a crucial
event required for mounting protective immune responses against fungal patho-
gens (5). During infection, innate immune cells, e.g., monocytes and macrophages,
rewire their energy metabolism from oxidative phosphorylation to glycolysis to rap-
idly and efficiently support antimicrobial functions, such as phagocytosis and pro-
duction of inflammatory mediators (6). The critical role of glucose metabolism dur-
ing infection is further supported by experimental evidence demonstrating that its
blockade dampens the immune response and hampers the clearance of selected
bacterial and fungal pathogens (7–11). In turn, pathogens have also developed com-
plex virulence strategies to exploit and subvert the metabolic requirements of
immune cells to their benefit (12, 13).
The recognition of pathogen-associated molecular patterns (PAMPs) drives substan-
tial changes in cellular metabolism and effector functions of immune cells (14). The
fungal cell wall contains a considerable diversity of PAMPs, including b-1,3-glucan,
melanin, and chitin (15, 16), capable of promoting the metabolic and functional
reprogramming of immune cells. For example, stimulation of monocytes with b-1,3-
glucan promotes metabolic and epigenetic changes underlying the acquisition of a
“trained immunity” phenotype characterized by enhanced cytokine production in
response to heterologous secondary stimulation (7, 17–20). More recently, the removal
of fungal melanin within the phagosomal compartment of macrophages was estab-
lished as the activating signal required for the induction of glucose metabolism in
immune cells during infection with Aspergillus fumigatus (8).
The upregulation of glycolytic enzymes upon infection also directly supports cyto-
kine expression through mechanisms that involve “moonlighting” activities (21, 22).
The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) enzyme is a
master regulator of the glycolytic pathway (23). By orchestrating the balance between
the synthesis and degradation of fructose-2,6-bisphosphate, it acts as an allosteric acti-
vator of 6-phophofructo-1-kinase, the rate-limiting enzyme in glycolysis (24). As a result
of its glycolysis-promoting activity, PFKFB3 has been shown to coordinate antiviral
effector functions of macrophages (25) and to be highly expressed in myeloid cells
from critically ill coronavirus disease 2019 (COVID-19) patients (26). Also, PFKFB3 has
been shown to be a target of the zinc fingers and homeoboxes 2 (ZHX2) transcription
factor and, as a result, to accelerate disease progression in models of sepsis (27).
Since the risk of infection varies considerably even among patients with
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comparable immune dysfunction and predisposing clinical factors, susceptibility to IPA
is thought to depend largely on genetic predisposition (28–32). However, the potential
involvement of variation in genes involved in glucose metabolism during the develop-
ment of IPA has never been addressed. Here, we describe the association of genetic
variation in PFKFB3 with an increased risk for developing IPA in HSCT patients as the
result of a defective metabolic reprogramming and downstream antifungal effector
functions of macrophages. Collectively, our results pinpoint a novel genetic factor reg-
ulating metabolic responses in immune cells and provide support for risk stratification
and preventive measures aimed at a more effective management of IPA.
RESULTS
The PFKFB3 locus influences cytokine production during fungal infection. We
have recently demonstrated that activation of glycolysis is required for effective
immune responses against A. fumigatus (8). We, therefore, examined whether variation
in genes involved in the glycolytic pathway affected host responses to fungal infection.
To do so, we tested the association of common single nucleotide polymorphisms
(SNPs) (minor allele frequency,$5%) in relevant candidate genes with differential cyto-
kine production after fungal stimulation of peripheral blood mononuclear cells
(PBMCs) from healthy individuals of the 500FG cohort in the Human Functional
Genomics Project (HFGP).
We identified a total of 107 cytokine quantitative trait loci (cQTLs) in three genes
involved in glucose metabolism, namely, PFKFB3, HK2, and AKT1 (see Table S1 in the
supplemental material). Although these were not different at a genome-wide level,
several strong cQTLs were identified in PFKFB3 displaying an uncorrected P value of
,0.05. We next assessed linkage disequilibrium (LD) between the SNPs in PFKFB3 (see
Fig. S1 in the supplemental material) and identified rs674430 and rs646564 to repre-
sent suitable candidates tagging the largest LD blocks influencing the production of
multiple cytokines (Table S1). Specifically, the rs674430 SNP was associated with a ge-
notype-dependent effect on the production of tumor necrosis factor (TNF) (overall P =
0.012) and interleukin 6 (IL-6) (overall P = 0.013) by PBMCs after 24 h of infection
(Fig. 1A), whereas the rs646564 SNP influenced gamma interferon (IFN-g) (overall P =
0.011) and IL-22 (overall P = 0.016) produced by cells stimulated for 7 days (Fig. 1B).
Collectively, these findings suggest genetic variation in PFKFB3 as an important regula-
tor of cytokine production in response to A. fumigatus infection.
Genetic variation at the PFKFB3 locus increases the risk of IPA after HSCT.
Because of the critical role of SNPs in PFKFB3 in regulating cytokine production, we
next investigated the relationship between genetic variants at this locus and suscepti-
bility to IPA in a disease-relevant context. We, therefore, assessed the cumulative inci-
dence of IPA in patients from the IFIGEN cohort undergoing allogeneic HSCT (Table 1)
according to recipient or donor PFKFB3 genotypes at the rs674430 or rs646564 SNPs.
FIG 1 The PFKFB3 locus influences the production of cytokines by PBMCs. (A) Levels (log2) of TNF and IL-6 according to rs674430
genotypes, and (B) IFN-g and IL-22 according to rs646564 genotypes detected after stimulation of PBMCs from the 500FG cohort with A.
fumigatus for 24 h or 7 days, respectively. Data are expressed as mean values 6 standard errors of the means (SEM). Overall P values were
determined using a linear regression model with age and gender as covariates.
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Age at transplantation, no. (%)
#20 yrs 13 (14.3) 69 (19.8) 0.264
21–40 yrs 23 (25.3) 101 (29.0)
.40 yrs 55 (60.4) 178 (51.2)
Gender, no. (%)
Female 38 (41.8) 150 (43.1) 0.859
Male 53 (58.2) 198 (56.9)
Underlying disease, no. (%)
Acute leukemia 49 (53.8) 179 (51.5) 0.115
Lymphoproliferative diseases 14 (15.4) 69 (19.8)
Myelodysplastic/myeloproliferative diseases 13 (14.3) 30 (8.6)
Chronic myeloproliferative diseases 7 (7.7) 20 (5.7)
Aplastic anemia 6 (6.6) 17 (4.9)
Other 2 (2.2) 33 (9.5)
Transplantation type, no. (%)
Matched, related 34 (37.4) 169 (48.6) 0.037
Matched, unrelated 33 (36.3) 81 (23.3)
Mismatched, related 0 (0.0) 7 (2.0)
Mismatched, unrelated 24 (26.4) 91 (26.2)
Graft source, no. (%)
Peripheral blood 80 (87.9) 287 (82.5) 0.506
Bone marrow 10 (11.0) 53 (15.2)
Cord blood 1 (1.1) 8 (2.3)
Disease stage, no. (%)
First complete remission 49 (53.8) 188 (54.0) 0.800
Second or subsequent remission, or relapse 13 (14.3) 59 (17.0)
Active disease 29 (31.9) 101 (29.0)
Conditioning regimen, no. (%)
RIC 68 (74.7) 228 (65.5) 0.091
Myeloablative 23 (25.3) 120 (34.5)
CMV serostatus of donor and recipient, no. (%)
D2/R1 or D1/R1 80 (87.9) 313 (89.9) 0.504
D2/R2 or D1/R2 11 (12.1) 35 (10.1)
Duration of neutropenia,d mean days (range) 13.1 (8–39) 13.5 (5–35) 0.460
Acute GVHD, no. (%)
No GVHD or grades I–II 63 (69.2) 302 (86.8) 0.0002
Grades III–IV 28 (30.8) 46 (13.2)
Antifungal prophylaxis, no. (%)e
Fluconazole 42 (46.2) 117 (33.6) 0.002
Posaconazole 26 (28.6) 107 (30.8)
Other 9 (9.9) 14 (4.0)
None or unknown 14 (15.4) 110 (31.6)
aTwenty-one patients with “possible” IPA were excluded. Lymphoproliferative diseases included cases of chronic
lymphocytic leukemia, multiple myeloma, and B- and T-cell lymphomas. Chronic myeloproliferative diseases
included cases of chronicmyelogenous leukemia and primary myelofibrosis. Other diseases included cases of
idiopathic medullar aplasia, lymphohistiocytosis, hemoglobinopathies, and paroxysmal nocturnal hemoglobinuria.
bRIC, reduced intensity conditioning; CMV, cytomegalovirus; D, donor; R, recipient; GVHD, graft-versus-host-disease.
cThe number of transplant recipients (percentage) with the characteristic are shown.
dNeutropenia was defined as#0.5 109 cells/liter.
eOther antifungals used in prophylaxis included voriconazole, liposomal amphotericin B, itraconazole and
caspofungin. P values were calculated by Fisher’s exact probability t test or Student’s t test for continuous
variables.
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Our results demonstrate that the donor, but not the recipient, rs646564 was associated
with an increased risk of IPA after transplantation (Fig. 2A). The cumulative incidence of
IPA for donor rs646564 was 31% for TT (P = 0.02), 23% for GT (P = 0.21), and 18% for GG
genotypes (reference), respectively. In contrast, no significant association with the risk of
IPA was detected for rs6744330 (Fig. 2B). In a multivariate model accounting for patient
age and gender, hematological malignancy, type of transplantation, conditioning regi-
men, development of acute graft-versus-host-disease (GVHD) grade III-IV and antifungal
prophylaxis, the donor TT genotype conferred a 2.7-fold increased risk of developing IPA
(P = 0.0017) (Table 2). These results highlight genetic variation at the PFKFB3 locus in the
donor compartment as a critical risk factor regulating susceptibility to IPA after HSCT.
The rs646564 SNP impairs PFKFB3-mediated activation of glycolysis. To under-
stand the mechanisms through which rs646564 might impact the metabolic homeo-
stasis of immune cells and contribute to antifungal immune responses, we next
assessed the expression of PFKFB3 in macrophages from healthy donors carrying dif-
ferent rs646564 genotypes after infection with A. fumigatus. In line with its enhanced
transcriptional activity (8), the expression of the PFKFB3 protein was also increased
early after infection (Fig. 3A). However, induction of PFKFB3 was instead markedly
impaired in macrophages carrying the TT genotype compared to cells from GG carriers.
The treatment with 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), despite its role
as a selective inhibitor of PFKFB3, also promoted a slight decrease in the expression of
PFKFB3 (Fig. 3B). In line with its impact on PFKFB3 expression, the rs646564 SNP was
found to significantly impair glucose consumption by both unstimulated and 24-h-
infected macrophages with the TT genotype (Fig. 3C). Macrophages from TT carriers
also secreted smaller amounts of lactate than cells with the GG genotype under the
same conditions (Fig. 3D), a finding ultimately pointing to a defective activation of the
glycolytic pathway in carriers of the T allele. In support of these findings, inhibition of
PFKFB3 with 3PO resulted in effects similar to those of the TT genotype on lactate
secretion (Fig. 3D), although not glucose consumption (Fig. 3C). These results
FIG 2 Genetic variation in PFKFB3 influences the risk of IPA. Cumulative incidence of IPA in 439
eligible HSCT recipients from the IFIGEN cohort according to the recipient or donor PFKFB3
genotypes at rs646564 (A) and rs674430 (B). Data were censored at 24months, and relapse and
death were competing events. P values are for Gray’s test.
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demonstrate that the rs646564 SNP contributes to IPA by compromising the efficient
activation of glycolysis by macrophages in response to fungal infection.
The rs646564 SNP compromises antifungal effector functions of macrophages.
To mount a protective immune response during infection with A. fumigatus, effector
functions of macrophages such as the production of proinflammatory cytokines, phag-
ocytosis, and killing activity are required (16). We tested therefore how the impairment
of glycolysis driven by the rs646564 SNP in PFKFB3 might affect these antifungal mech-
anisms. Besides influencing the production of the adaptive cytokines IFN-g and IL-22
(Fig. 1B), the TT genotype also impaired the secretion of proinflammatory cytokines,
but not IL-10, by macrophages after 24 h of infection (Fig. 4A), a finding illustrating
likely distinct regulatory mechanisms mediated by rs646564 across cell types. A com-
parable defect in cytokine secretion by infected macrophages was also observed after
the pharmacological inhibition of PFKFB3 (Fig. 4A). In addition, the conidiacidal activity of
macrophages from TT carriers was also significantly decreased compared to cells with the
TABLE 2Multivariate analysis of the association between rs646564 in PFKFB3 and risk of IPAa
Genetic or clinical variable
Adjusted HRb (95% CI)
(n=439) P value
Donor TT at rs646564 2.72 (1.46–5.06) 0.0017
aGVHD III-IV 3.84 (1.46–10.1) 0.0062
aMultivariate analyses were based on the subdistribution regression model of Fine and Gray. aGVHD, acute graft-
versus-host-disease.
bHazard ratios were adjusted for patient age and gender, hematological malignancy, type of transplantation,
conditioning regimen, development of acute GVHD (aGVHD) grade III-IV and antifungal prophylaxis. Only the
variables remaining significant after adjustment are shown. HR, hazard ratio; CI, confidence interval.
FIG 3 The rs646564 SNP in PFKFB3 inhibits the activation of glycolysis in macrophages. (A and B) Expression of
PFKFB3 in macrophages infected with A. fumigatus for 2 h according to different rs646564 genotypes (A) or
following treatment with 3PO (representative of three independent experiments) (B). The pixel density of the
PFKFB3 was normalized to b-actin. (C and D) Glucose consumption (C) and lactate secretion (D) by
macrophages left untreated or infected with A. fumigatus for 24 h, according to different rs646564 genotypes
or following treatment with 3PO. Data are expressed as mean values 6 SEM. Ctrl, control.
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GG genotype (Fig. 4B), an effect that could, at least in part, be explained by the impaired
production of reactive oxygen species (ROS) by TT macrophages after infection with
A. fumigatus (Fig. 4C). Likewise, the conidiacidal activity (Fig. 4B) was also similarly
impaired upon treatment with 3PO. In contrast, the phagocytic ability of macrophages
was not compromised in either the presence of the TT genotype or 3PO-treated macro-
phages (Fig. 4D). These results confirm a critical role for PFKFB3 in the induction and regu-
lation of antifungal effector functions of macrophages in response to A. fumigatus.
Genetic variation at the PFKFB3 locus regulates the alveolar cytokine profile in
IPA. To examine whether the rs646564 SNP also regulated cytokine production in IPA
patients, we next profiled the concentration of relevant cytokines in bronchoalveolar
lavage fluid (BAL) samples collected from patients enrolled in the FUNBIOMICS study
at diagnosis of fungal infection (33). We found that the alveolar concentrations of IL-
1b and IL-6 were lower among patients carrying the TT genotype than GG carriers
(Fig. 5A). In line with their regulation by the rs646564 SNP in PBMCs (Fig. 1B), produc-
tion of T cell-derived cytokines was also influenced, with lower concentrations of IL-
17A and IL-22 detected in samples from TT carriers compared to GG carriers (Fig. 5B).
Collectively, these findings illustrate a critical link between genetic variation in the gly-
colytic pathway and the activation of immune responses in patients with IPA and may
explain the association with susceptibility to infection.
DISCUSSION
Several factors are known to predispose to fungal disease, particularly in immuno-
compromised and severely ill patients, but these alone fail to explain the development
FIG 4 Antifungal effector mechanisms of macrophages are impaired by the rs646564 SNP in PFKFB3. (A) Production of
IL-1b , TNF, IL-6, and IL-10 by macrophages infected with A. fumigatus for 24 h according to different rs646564
genotypes or following treatment with 3PO. (B) Conidiacidal activity of macrophages according to different rs646564
genotypes or following treatment with 3PO. (C) Production of cytosolic ROS (left) and mitochondrial ROS (right) by
macrophages infected with A. fumigatus for 4 h according to different rs646564 genotypes or following treatment with
3PO. Data are expressed as mean fluorescence intensity (MFI). DHE, dihydroethidium. (D) Phagocytosis of macrophages
according to different rs646564 genotypes or following treatment with 3PO. Data are expressed as mean values 6
SEM.
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of infection in all affected patients. Several studies have reported an expanding num-
ber of common SNPs associated with the development of IPA in at-risk patients (28,
30). On the basis of their validation across independent cohorts (32), the most robust
markers for IPA identified thus far include well-known components of the immune
response to A. fumigatus, such as the soluble pattern recognition molecule pentraxin-3
(PTX3) (29, 32) and the C-type lectin receptor dectin-1 (31, 34). However, no evidence
disclosing a relevant contribution of the host genetic profile to the immunometabolic
responses activated in response to A. fumigatus has been disclosed thus far. We now
demonstrate that genetic variation in PFKFB3 contributes to IPA via molecular mecha-
nisms influencing the metabolic homeostasis of immune cells and the signals that
orchestrate cytokine production and fungal clearance.
To counter fungal infection, myeloid cells undergo metabolic reprogramming via
distinct mechanisms whereby enhanced glycolysis fuels antimicrobial effector func-
tions required for effective clearance of the pathogen (8, 19). A key step in the regula-
tion of the glycolytic pathway is the PFKFB3-mediated control of the levels of the fruc-
tose-2,6-bisphosphate metabolite. Our data disclose a genetic variant associated with
defective activation of PFKFB3 following fungal infection. These results are in line with
previous reports demonstrating that the genetic inactivation of PFKFB3 in murine cells
was shown to disrupt glycolysis and innate defenses against other infections such as
infection by the respiratory syncytial virus (25). Likewise, the defective induction of
PFKFB3 in T cells from rheumatoid arthritis patients was reported to drive a hypoglyco-
lytic phenotype, impairing ATP generation, the redox balance, and the production of
ROS. In contrast, overexpression of PFKFB3 in patient T cells enhances the glycolytic
flux and protects cells from excessive apoptosis (35). These findings highlight PFKFB3
as a critical regulatory node at the interface of metabolism and immunity.
We demonstrate that the activation of PFKFB3 is critical for the regulation of cyto-
kine production and antifungal effector functions in macrophages. The activation of
the NLRP3 inflammasome in macrophages and the subsequent release of IL-1b have
been found to modulate glycolysis via PFKFB3 (36). Importantly, genetic variation in
PFKFB3 is correlated with differential production of IL-1b after fungal infection, sug-
gesting the existence of bidirectional signaling events, in which PFKFB3 may also be
able to regulate the activation of the NLRP3 inflammasome to drive the production
of IL-1b . Endothelial PFKFB3 expression was also found to be increased after TNF
treatment (37), and IL-6 was reported to enhance glycolysis in mouse embryonic
fibroblasts and human cell lines by upregulating PFKFB3 expression (38). These
results suggest the existence of a reciprocal regulation between production of
proinflammatory cytokines and PFKFB3 activation. However, where the cross talk
FIG 5 PFKFB3 regulates cytokine production in IPA. (A and B) Levels of IL-1b , TNF, and IL-6 (A) and
IFN-g, IL-17, and IL-22 (B) in BAL fluid samples from patients diagnosed with IPA (n= 16 for GG; n= 7
for TT). Data are expressed as mean values 6 SEM.
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between these mechanisms occurs remains unclear. Recent reports highlight that,
although the activity of PFKFB3 as a major regulator of glycolysis occurs mostly in
the cytosol, it is also able to mediate glycolysis-independent nuclear roles (27). This
suggests that PFKFB3 can, directly or indirectly, modulate and interact with the NF-
κB pathway to regulate inflammatory responses.
PFKFB3 has a largely detrimental role in supporting cancer cell growth, by promot-
ing glycolysis, cell cycle progression, and angiogenesis (39). In this sense, and although
the inactivation of PFKFB3 is regarded as a promising therapeutic opportunity across
several types of cancer (24, 40), we hypothesize that the balanced induction of this
enzyme specifically in immune cells may instead represent a valuable strategy benefit-
ing patients suffering from IPA, especially those harboring loss-of-function SNPs in
PFKFB3. Accordingly, the activation of PFKFB3 has been shown to accelerate disease
progression in models of sepsis (27). In this context, the inhibition of PFKFB3 could be
therapeutically exploited to dampen the pathogenic activation of glycolysis, and there-
fore, it is not surprising that such approaches have been shown to alleviate sepsis-
related acute lung injury by suppressing inflammatory responses and the apoptosis of
alveolar epithelial cells (41).
Current limitations in the management of fungal diseases, as well as concerns over
the emergence of antifungal resistance, are inspiring the search for novel host-directed
therapies. Our expanded understanding of how metabolic networks coordinate
immune cell function and how specific genetic signatures influence immunometabolic
responses and regulate susceptibility to fungal disease is opening new horizons to-
ward personalized medical interventions based on individual genomics. The renewed
interest in immunometabolism is expected to improve our understanding of how
these signaling networks coordinate immune cell function, ultimately paving the way
toward innovative therapeutic approaches involving adjuvant immunotherapy to reor-
ient host cells toward immune protection in the context of fungal infections.
MATERIALS ANDMETHODS
Ethics statement. Approval for the IFIGEN study was obtained from the Ethics Subcommittee for
Life and Health Sciences (SECVS) (no. 125/014), the Ethics Committee for Health of the Instituto
Português de Oncologia, Porto, Portugal (no. 26/015), the Ethics Committee of the Lisbon Academic
Medical Center, Portugal (no. 632/014), and the National Commission for the Protection of Data,
Portugal (no. 1950/015). The FUNBIOMICS study was approved by SECVS (no. 126/2014) and the Ethics
Committee of the University Hospitals of Leuven, Belgium. The Human Functional Genomics Project
(HFGP) study was approved by the Ethical Committee of Radboud University Nijmegen, the Netherlands
(no. 42561.091.12). Experiments were conducted according to the principles expressed in the
Declaration of Helsinki, and participants provided written informed consent. The functional experiments
involving cells isolated from the peripheral blood of healthy volunteers at the Hospital of Braga,
Portugal, was approved by the SECVS of the University of Minho, Portugal (no. 014/015).
Population cohorts. The functional experiments were performed in healthy individuals of Western
European ancestry recruited at the Hospital de Braga, Braga, Portugal, and in the 500FG cohort from the
HFGP, which comprises 534 Dutch healthy individuals of Western European ancestry. The genetic associ-
ation study with IPA was performed with a total of 460 hematological patients of European ancestry
undergoing allogeneic HSCT at Instituto Português de Oncologia, Porto, Portugal, and at Hospital de
Santa Maria, Lisbon, Portugal, enrolled in the IFIGEN study between 2009 and 2015. Of these, 439 had
available donor and recipient DNA samples and patient-level data. The demographic and clinical charac-
teristics of the patients are summarized in Table 1. Ninety-one cases of probable/proven IPA were identi-
fied according to the standard criteria from the European Organization for Research and Treatment of
Cancer/Mycology Study Group (EORTC/MSG) (42). Twenty-one patients were excluded from the study
based on the “possible” classification of infection.
SNP selection and genotyping. Genomic DNA was isolated from whole blood using the QIAcube
automated system (Qiagen). SNPs were selected based on their putative role as cytokine QTLs in the
HFGP study and on their ability to tag surrounding variants with a pairwise correlation coefficient r2 of at
least 0.80 and a minor allele frequency of $5% using publicly available sequencing data from Pilot 1 of
the 1000 Genomes Project for the CEU population. Genotyping of rs674430 and rs646564 SNPs in
PFKFB3 was performed using KASPar assays (LGC Genomics) in an Applied Biosystems 7500 fast real-
time PCR system (Thermo Fisher Scientific), according to the manufacturer’s instructions. The DNA sam-
ples of individuals from the 500FG cohort were genotyped using the commercially available chip
Illumina HumanOmniExpressExome-8 v1.0. Quality control and imputation were performed as described
previously (43).
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Cytokine QTL mapping. Following the generation of genotype and cytokine data, cytokine QTLs
were mapped as described previously (43). Briefly, concentrations of human cytokines were determined
using specific commercial enzyme-linked immunosorbent assay (ELISA) kits (PeliKine Compact, or R&D
Systems), per the manufacturer’s instructions. Cytokine QTLs were identified by log-transforming raw
cytokine levels and mapping them to genotype data using a linear regression model with age, gender,
and cell counts as covariates.
Generation of monocyte-derived macrophages. Buffy coats from healthy donors were obtained af-
ter written informed consent. Briefly, peripheral blood mononuclear cells (PBMCs) were enriched from buffy
coats by density gradient using Histopaque-1077 (Sigma-Aldrich). Cells present in the enriched mononu-
clear fraction were washed twice in phosphate-buffered saline (PBS) and resuspended in RPMI 1640 culture
medium with 2mM glutamine (Thermo Fisher Scientific) supplemented with 10% human serum (Sigma-
Aldrich), 10 U/ml penicillin-streptomycin, and 10mM HEPES (Thermo Fisher Scientific). Monocytes were
then separated using positive magnetic bead separation with anti-CD141-coated beads (MACS Miltenyi)
according to the manufacturer’s instructions. To evaluate the purity of the isolated monocyte population,
5 105 cells were stained with a BV 650 anti-human CD14 (clone M5E2) antibody for 30min at 4°C. Cell via-
bility was assessed by staining with Zombie Green fluorescent dye (BioLegend) for 30min at 4°C. Pellets
were washed and resuspended in fluorescence-activated cell sorting (FACS) buffer (PBS containing 2% fetal
bovine serum [FBS] and 2mM EDTA) prior to analysis. Data were obtained on a BD FACS LSRII instrument
(Becton Dickinson) and processed using FlowJo (Tree Star Inc.). The obtained CD141 populations displayed
a purity higher than 94% and yielded more than 97% viable cells. Isolated monocytes were then resus-
pended in complete RPMI medium and seeded at a concentration of 1 106 cells/ml in 24-well and 96-well
plates (Corning Inc.) for 7 days in the presence of 20ng/ml of recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF; Miltenyi Biotec). Acquisition of macrophage morphology was confirmed
by visualization with a BX61 microscope (Olympus, Tokyo, Japan).
Stimulation of MDMs. Unless otherwise indicated, monocyte-derived macrophages (MDMs) (5 105/
well in 24-well plates) were either left untreated or stimulated with live conidia of A. fumigatus at a 1:5 or
1:10 effector-to-target ratio, respectively, for 24h at 37°C and 5% CO2. In some conditions, MDMs were pre-
treated for 4 h with 30mM 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) to inhibit PFKFB3 activity. In
all experiments, data were assessed in triplicates and are shown as the mean value for each individual.
Quantification of glucose and lactate by HPLC. After infection, supernatants were removed, centri-
fuged, and transferred to high-performance liquid chromatography (HPLC) tubes. Glucose and lactate
levels were determined using a Gilson pump system (Gilson) with a 54°C HyperREZ XP Carbohydrate H1
8-mm (Thermo Fisher Scientific) column and a refractive index detector (IOTA 2; Reagents). The mobile
phase consisting of 0.0025 M H2SO4 was filtered and degasified for at least 45min before use. Standard
solutions were prepared in MilliQ water (Millipore). All data were analyzed using the Gilson Uniprot soft-
ware, version 5.11.
Phagocytosis assay. To evaluate phagocytosis, MDMs (5 105/well, in 24-well plates) were infected
with fluorescein isothiocyanate (FITC)-labeled conidia of A. fumigatus at a 1:5 effector-to-target ratio. The
infection was synchronized for 30min at 4°C, and phagocytosis was initiated by shifting the coincuba-
tion to 37°C at 5% CO2 for 1 h. Phagocytosis was stopped by washing wells with PBS, and extracellular
conidia were stained with 0.25mg/ml Calcofluor White (Sigma-Aldrich) for 15min at 4°C to avoid further
ingestion. After the wells were washed twice with PBS, the cells were fixed with PBS containing 3.7%
(vol/vol) formaldehyde for 15min. The number of MDMs with ingested green conidia was enumerated
by examining the slides by fluorescence microscopy (Olympus), and data were expressed as the percent-
age of MDMs that internalized one or more conidia.
Conidiacidal activity assay. Following differentiation, MDMs (1 105/well, in 96-well plates) were
stimulated with live A. fumigatus conidia at a 10:1 effector-to-target ratio for 1 h at 37°C and 5% CO2 to
allow the internalization of conidia. Medium containing the noningested conidia was removed, and wells
were washed twice with PBS. To measure the conidiacidal activity, MDMs were allowed to eliminate the
internalized conidia for 2h at 37°C in 5% CO2. After incubation, culture plates were snap-frozen at 280°C
and thawed at 37°C to cause cell lysis and release of ingested conidia. Serial dilutions of cell lysates were
plated on solid growth media, and following a 24-h incubation at 37°C, the number of colony-forming units
(CFU) was enumerated, and the percentage of CFU inhibition was calculated.
Measurement of ROS production. MDMs (5 105/well, in 24-well plates) were infected with live A.
fumigatus conidia at a 1:5 effector-to-target ratio for 4 h at 37°C and 5% CO2. After infection, the culture
medium was removed, and cells were trypsinized for 10min at 37°C. Then, cells were collected and cen-
trifuged for 5min at 2,000 rpm. Finally, each pellet was resuspended in 10mM dihydroethidium (cyto-
solic ROS) or 5mM Mitosox (mitochondrial ROS) (Thermo Fisher Scientific), and cells were then incubated
for 30min at 37°C, protected from light. Data were obtained on a BD FACS LSRII instrument (Becton
Dickinson) and processed using FlowJo (Tree Star Inc.).
ELISA. MDMs (5 105/well in 24-well plates) were infected with A. fumigatus conidia at a 1:5 or 1:10
effector-to-target ratio, respectively, for 24h at 37°C and 5% CO2. After infection, supernatants were col-
lected, and cytokine levels were quantified using ELISA MAX Deluxe Set kits (BioLegend), according to the
manufacturer’s instructions. Cytokine measurements in BAL samples were performed using the Human
Premixed Multi-Analyte kit (R&D Systems), according to the manufacturer’s instructions.
Western blot analysis. MDMs (5 105/well, in 24-well plates) were infected with A. fumigatus coni-
dia for 2 h at a 1:10 effector-to-target ratio at 37°C in 5% CO2. After infection, cells were lysed in radioim-
munoprecipitation assay (RIPA) buffer (50mM Tris, 250mM NaCl, 2mM EDTA, 1% NP-40, 10% glycerol
[pH 7.2], and a mixture of protease inhibitors [Roche Molecular Biochemicals]). Cell lysis was performed
at 4°C for 30min (with shaking), and samples were then centrifuged. The protein content was
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determined using the Bradford dye-binding (Bio-Rad) method. Laemmli buffer (Bio-Rad) was added to
20mg of protein, and samples were boiled and separated on a 12% sodium dodecyl sulfate-polyacryl-
amide gel (SDS-PAG) and transferred to nitrocellulose membranes (Bio-Rad). Western blotting was per-
formed according to the manufacturer’s instructions, using the following primary antibodies: rabbit anti-
PFKFB3 and mouse anti-b-actin, both from Abcam and diluted 1:1,000. Secondary antibodies used were
anti-rabbit (Thermo Fisher Scientific) and anti-mouse (Bio-Rad), both diluted to 1:5,000. The blots were
developed using chemiluminescence (SuperSignal West Femto maximum sensitivity substrate; Thermo
Fisher Scientific) and detected with ChemiDoc XRS system (Bio-Rad). Signal intensities and quantifica-
tions were determined with the ImageLab 4.1 analysis software (Bio-Rad).
BAL fluid collection. BAL specimens were collected as previously described (33). Briefly, specimens
were collected using a flexible fiber-optic bronchoscope following local anesthesia with 2% lidocaine
(Xylocaine), when infection was clinically suspected. Samples were obtained by instillation of a pre-
warmed 0.9% sterile saline solution (20ml twice). The sampling area was determined based on the local-
ization of the lesion on chest imaging (X-ray or computed tomography scan). BAL specimens with com-
parable recovery rates were used. All samples were stored at280°C until use.
Statistical analysis. The probability of IPA according to PFKFB3 genotypes was determined using
the cumulative incidence method and compared using Gray’s test (44). Cumulative incidences at
24months were computed with the cmprsk package for R version 2.10.1 (45), with censoring of data at
the date of the last follow-up visit and relapse and death as competing events. All clinical and genetic
variables achieving a P value of #0.15 in the univariate analysis were entered one by one in a pairwise
model together and kept in the final model if they remained significant (P , 0.05). Multivariate analysis
was performed using the subdistribution regression model of Fine and Gray with the cmprsk package
for R (46). Data obtained in functional assays were expressed as means 6 standard errors of the means
(SEM). Unpaired Student’s t test with Bonferroni’s adjustment and two-tailed Mann-Whitney rank sum
test were used to determine statistical significance (P, 0.05).
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